Registration - In-house Corporation

Merck Canada Inc. / David D. Jones, PRESIDENT

Registration Information

In-house Corporation name: Merck Canada Inc.
Previous in-house corporation names
Responsible Officer Name: David D. Jones, PRESIDENT
Responsible Officer Change History
Initial registration start date: 2001-02-01
Registration status: Active
Registration Number: 959141-12241

Associated Communications

Total Number of Communication Reports: 202

Monthly communication reports in the last 6 months: 3

Version 22 of 46 (2012-05-31 to 2012-08-09)

Registration versions:

Version 22 of 46 (2012-05-31 to 2012-08-09)

Lobbying Information

Subject Matters

Aboriginal Affairs
Agriculture
Constitutional Issues
Consumer Issues
Defence
Education
Employment and Training
Energy
Environment
Financial Institutions
Government Procurement
Health
Immigration
Industry
Infrastructure
Intellectual Property
Internal Trade
International Relations
International Trade
Justice and Law Enforcement
Labour
Regional Development
Science and Technology
Small Business
Sports
Taxation and Finance
Telecommunications
Tourism
Transportation

Subject matters added through a monthly communication report

Economic Development
Research and Development

Subject Matter Details

Legislative Proposal, Bill or Resolution

Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry.
Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products.
Income Tax Act as it relates to biopharmaceutical products.
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.

Legislative Proposal, Bill or Resolution, Regulation

Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.

Policies or Program

Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility".
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs.
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union.
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products.
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB).
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits.
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations.
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG).

Regulation

Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
New Substances Notification Regulations as it relates to the biopharmaceutical industry.
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products.
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
Smart Regulations as it relates to the biopharmaceutical industry.

Communication Techniques

Written communication
Oral communication
Grass-roots communication

Government Institutions

Agriculture and Agri-Food Canada (AAFC)
Canadian Institutes of Health Research (CIHR)
Canadian International Development Agency (CIDA)
Canadian International Trade Tribunal (CITT)
Competition Tribunal (CT)
Environment Canada
Finance Canada (FIN)
Fisheries and Oceans Canada (DFO)
Foreign Affairs and International Trade Canada (DFAITC)
Health Canada (HC)
House of Commons
Human Resources and Skills Development Canada (HRSDC)
Industry Canada
Justice Canada (JC)
Members of the House of Commons
National Research Council (NRC)
Natural Resources Canada (NRCan)
Natural Sciences and Engineering Research Council (NSERC)
Office of the Information Commissioner of Canada (OIC)
Office of the Privacy Commissioner of Canada (OPC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Works and Government Services Canada
Senate of Canada
Solicitor General Canada (SGC)
Statistics Canada (StatCan)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

In-house Corporation Details

Description of activities

Today’s Merck is working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, consumer and animal health products. In Canada, Merck markets more than 530 pharmaceutical, consumer and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines, women's health and sun care, and is focused on expanding offerings in other areas, including virology, oncology and diabetes. Based in Montréal, Québec, Merck employs more than 1250 people across Canada. The Merck Canada manufacturing facility in Québec has been designated by its parent company as a Centre of Excellence for the global production of liquids, ointments and creams. Merck is one of the top R&D investors in Canada, with investments totalling $78.6 million in 2010. For more information about our operations in Canada, visit www.merck.ca.

Responsible officer name and position during the period of this registration

Cyril Schiever, PRESIDENT

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
16711 TransCanada Highway
Kirkland, QC H9H 3L1
Canada

Telephone number: 514-428-2638
Fax number: 514-428-2662

Parent Company Information

MERCK FROSST COMPANY
- 1959 Upper Water Street
  Suite 900
  Halifax, NS B3J 2X2
  Canada

Subsidiary Beneficiary Information

Merck Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Jennifer Chan, Vice President, Policy & Communications | No public offices held
Tama Donoahue-Walker, Vice President, Patient Access | No public offices held
Jeffrey Malawski, National Manager, Public Health | No public offices held
Cyril Schiever, President | No public offices held
Sandra Wainwright, Director - Regulatory Affairs | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Kathy Armstrong, Manager, Patient Access - Ontario | No public offices held
Christian Blouin, Director, Public Health & Government Relations | No public offices held
Robert Livingston, Director, Federal Government Affairs | No public offices held
Wendy Morton, Manager, National Policy | No public offices held

Merck Canada Inc.

The following names have been used on or after July 2, 2008

Name	From	To
Merck Canada Inc.	2011-01-01	current
MERCK FROSST CANADA LTD.	2008-07-08	2011-01-01

The following names have been used before July 2, 2008

MERCK FROSST CANADA LTD.
MERCK FROSST CANADA INC

Merck Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
David D. Jones	2024-09-01	Current
Marwan Akar	2021-09-17	2024-09-01
Anna Van Acker	2017-12-14	2021-09-17
Chirfi Guindo	2014-10-01	2017-12-14
Thomas Cannell	2013-01-01	2014-10-01
Cyril Schiever	2011-07-01	2013-01-01
Carlos Dourado	2009-11-02	2011-07-01
DAWN GRAHAM	2001-02-01	2009-11-02

Date Modified:: 2025-06-17

Search and menus

Language selection

Registration - In-house Corporation

Merck Canada Inc. / David D. Jones, PRESIDENT

Registration Information

Associated Communications

Version 22 of 46 (2012-05-31 to 2012-08-09)

Version 22 of 46 (2012-05-31 to 2012-08-09)

Subject Matters

Subject matters added through a monthly communication report

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties